APA (7th ed.) Citation

Cho, B. C., Felip, E., Hayashi, H., Thomas, M., Lu, S., Besse, B., . . . Spira, A. I. (2022). MARIPOSA: Phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future oncology (London, England), 18(6), 639. https://doi.org/10.2217/fon-2021-0923

Chicago Style (17th ed.) Citation

Cho, Byoung Chul, et al. "MARIPOSA: Phase 3 Study of First-line Amivantamab + lazertinib Versus Osimertinib in EGFR-mutant Non-small-cell Lung Cancer." Future Oncology (London, England) 18, no. 6 (2022): 639. https://doi.org/10.2217/fon-2021-0923.

MLA (9th ed.) Citation

Cho, Byoung Chul, et al. "MARIPOSA: Phase 3 Study of First-line Amivantamab + lazertinib Versus Osimertinib in EGFR-mutant Non-small-cell Lung Cancer." Future Oncology (London, England), vol. 18, no. 6, 2022, p. 639, https://doi.org/10.2217/fon-2021-0923.